Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma

被引:0
作者
Zhang, Jian [1 ,2 ]
Zhong, Xi [3 ]
Jiang, Huali [4 ]
Jiang, Hualong [5 ]
Xie, Tao [1 ,2 ]
Tian, Yunhong [1 ,2 ]
Li, Rong [1 ,2 ]
Wang, Baiyao [1 ,2 ]
Zhang, Jiexia [6 ]
Yuan, Yawei [1 ,2 ]
机构
[1] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Dept Radiat Oncol, Guangzhou 510095, Peoples R China
[2] Guangzhou Inst Resp Dis, State Key Lab Resp Dis, Guangzhou 510095, Peoples R China
[3] Guangzhou Med Univ, Radiat Dept, Affiliated Canc Hosp & Inst, Guangzhou 510095, Peoples R China
[4] Sun Yat Sen Univ, Dept Cardiovascularol, Tungwah Hosp, Dongguan 523000, Peoples R China
[5] Sun Yat Sen Univ, Dept Urol, Tungwah Hosp, Dongguan 523000, Peoples R China
[6] Guangzhou Med Univ, State Key Lab Resp Dis, Natl Clin Res Ctr Resp Dis, Guangzhou Inst Resp Hlth,Affiliated Hosp 1, Guangzhou 510120, Peoples R China
来源
AGING-US | 2020年 / 12卷 / 22期
关键词
head and neck squamous cell carcinoma; tumor microenvironment; immunotherapy; single nucleotide variants; copy number variations; PD-1; BLOCKADE; MUTATIONAL PROCESSES; BREAST-CANCER; COPY-NUMBER; EXPRESSION; RECURRENT; PEMBROLIZUMAB; LANDSCAPE; NIVOLUMAB; SIGNATURES;
D O I
暂无
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The tumor microenvironment (TME) constitutes a complex milieu of cells and cytokines that maintain equilibrium between tumor progression and prognosis. However, comprehensive analysis of the TME and its clinical significance in head and neck squamous cell carcinoma (HNSCC) remains to be unreported. In this study, based on large-scale RNA sequencing data pertaining to single nucleotide variants (SNVs) and copy number variations (CNVs) in HNSCC patients from The Cancer Genome Atlas database, we analysed subpopulations of infiltrating immune cells and evaluated the role of TME infiltration pattern (TME score) in assessing immunotherapy outcome. TME signature genes involved in several inflammation and immunity signalling pathways were observed in the TME score subtype, which were considered immunosuppressive and potentially responsible for significantly worse prognosis. In comparison with SNVand CNV-mediated tumor mutation burden, TME score can significantly differentiate between highand low-risk HNSCC and predict immunotherapy outcome. Our data provide clarity on the comprehensive landscape of interactions between clinical characteristics of HNSCC and tumor-infiltrating immune cells. TME score seems to be a useful biomarker that can predict immunotherapy outcome in HNSCC patients.
引用
收藏
页码:22509 / 22526
页数:18
相关论文
共 50 条
  • [41] Effect of tumor microenvironment on pathogenesis of the head and neck squamous cell carcinoma: a systematic review
    Peltanova, Barbora
    Raudenska, Martina
    Masarik, Michal
    [J]. MOLECULAR CANCER, 2019, 18 (1)
  • [42] Identification and validation of a prognostic signature and combination drug therapy for immunotherapy of head and neck squamous cell carcinoma
    Qiang, Weijie
    Dai, Yifei
    Xing, Xiaoyan
    Sun, Xiaobo
    [J]. COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2021, 19 : 1263 - 1276
  • [43] TMErisk score: A tumor microenvironment-based model for predicting prognosis and immunotherapy in patients with head and neck squamous cell carcinoma
    Li, Yu
    Pan, Xiaozhou
    Luo, Wenwei
    Gamalla, Yaser
    Ma, Zhan
    Zhou, Pei
    Dai, Chunfu
    Han, Dingding
    [J]. HELIYON, 2024, 10 (11)
  • [44] Immunotherapy for Head and Neck Squamous Cell Carcinoma
    Moskovitz, Jessica
    Moy, Jennifer
    Ferris, Robert L.
    [J]. CURRENT ONCOLOGY REPORTS, 2018, 20 (02)
  • [45] Alpelisib and Immunotherapy: A Promising Combination for Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
    Suleiman, Riham
    McGarrah, Patrick
    Baral, Binav
    Owen, Dawn
    Aguilera, Jesus Vera
    Halfdanarson, Thor R.
    Price, Katharine A.
    Bayne, Harry E. Fuentes
    [J]. CANCER REPORTS, 2024, 7 (10)
  • [46] Characteristic of Immunotherapy Trials in Head and Neck Squamous Cell Carcinoma: 2013-2023
    Xia, Binbin
    Wu, Fan
    Wei, Bin
    Li, Qunxing
    Lin, Hsinyu
    Lu, Peichia
    Xie, Zhijun
    Liu, Niu
    Wu, Jiaying
    Zhong, Jianglong
    Fan, Song
    [J]. ORAL DISEASES, 2025,
  • [47] Combinations of immunotherapy and radiation therapy in head and neck squamous cell carcinoma: a narrative review
    Hayman, Thomas J.
    Bhatia, Aarti K.
    Jethwa, Krishan R.
    Young, Melissa R.
    Park, Henry S.
    [J]. TRANSLATIONAL CANCER RESEARCH, 2021, 10 (05) : 2571 - 2585
  • [48] Comprehensive analysis of the relationship between RNA modification writers and immune microenvironment in head and neck squamous cell carcinoma
    Li, Wei
    Chen, Ying
    Zhang, Yao
    Wen, Wen
    Lu, Yingying
    [J]. BMC IMMUNOLOGY, 2024, 25 (01)
  • [49] Recent Advances in Immunotherapy for Patients with Head and Neck Cutaneous Squamous Cell Carcinoma
    Khorasanchi, Adam
    Wu, Richard
    Kendra, Kari
    Verschraegen, Claire
    [J]. CANCERS, 2022, 14 (21)
  • [50] Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy
    Vathiotis, Ioannis A.
    Johnson, Jennifer M.
    Argiris, Athanassios
    [J]. CANCER TREATMENT REVIEWS, 2021, 97